Marčec, R., Dodig, V. M. i Likić, R. (2023). Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?. Journal of Infection, 86. (1), 66-117. doi: 10.1016/j.jinf.2022.10.030
Marčec, Robert, et al. "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?." Journal of Infection, vol. 86, br. 1, 2023, str. 66-117. https://doi.org/10.1016/j.jinf.2022.10.030
Marčec, Robert, Vinko Michael Dodig i Robert Likić. "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?." Journal of Infection 86, br. 1 (2023): 66-117. https://doi.org/10.1016/j.jinf.2022.10.030
Marčec, R., Dodig, V. M. i Likić, R. (2023) 'Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?', Journal of Infection, 86(1), str. 66-117. doi: 10.1016/j.jinf.2022.10.030
Marčec R, Dodig VM, Likić R. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?. Journal of Infection [Internet]. 01.2023. [pristupljeno 07.09.2024.];86(1):66-117. doi: 10.1016/j.jinf.2022.10.030
R. Marčec, V. M. Dodig i R. Likić, "Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?", Journal of Infection, vol. 86, br. 1, str. 66-117, Siječanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:888007. [Citirano: 07.09.2024.]